SEPN
NEUTRALAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Graham Number and Intrinsic Value are unavailable due to lack of positive earnings.
- Low Debt/Equity
- P/S ratio of 25.54 is excessive
- Negative P/E and Forward P/E
Growth is driven by early-stage biotech milestones rather than sustainable cash flow.
- Massive revenue growth
- High analyst price targets ($44.43)
- Consistent earnings misses
Price performance has decoupled from fundamental earnings results.
- Exceptional 1-year price return
- Poor earnings track record
- Negative EPS progression
Altman Z-Score not provided, but F-Score indicates significant fundamental weakness.
- High Current and Quick ratios
- Piotroski F-Score of 2/9
- Negative ROE and ROA
Typical for growth-stage biotechnology companies.
- No dividend paid
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for SEPN and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
SEPN
Septerna, Inc.
Primary
|
+22.1% | +22.1% | +342.9% | +18.4% | +8.4% | +13.2% |
|
EYPT
EyePoint, Inc.
Peer
|
+41.6% | +326.8% | +243.1% | +2.1% | -9.6% | +8.8% |
|
ALVO
Alvotech
Peer
|
-65.9% | -71.8% | -66.2% | -52.0% | -17.7% | -1.6% |
|
IRMD
IRADIMED CORPORATION
Peer
|
+324.4% | +136.8% | +89.2% | +31.5% | -7.3% | -2.9% |
|
BLFS
BioLife Solutions, Inc.
Peer
|
-40.8% | -0.5% | -10.7% | +10.1% | -2.1% | +1.8% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
SEPN
Septerna, Inc.
|
NEUTRAL | $1.17B | - | -12.2% | -106.4% | $26.13 | |
|
EYPT
EyePoint, Inc.
|
NEUTRAL | $1.18B | - | -72.2% | -% | $14.17 | Compare |
|
ALVO
Alvotech
|
BEARISH | $1.19B | 16.61 | -% | 12.1% | $3.82 | Compare |
|
IRMD
IRADIMED CORPORATION
|
NEUTRAL | $1.19B | 53.37 | 24.8% | 26.8% | $93.4 | Compare |
|
BLFS
BioLife Solutions, Inc.
|
NEUTRAL | $1.2B | - | -5.2% | -3.2% | $24.87 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-02 | SHAIKHLY SAMIRA | Officer | Sale | 70,453 | $1,979,838 |
| 2026-03-02 | SHAIKHLY SAMIRA | Officer | Option Exercise | 70,453 | $129,456 |
| 2026-02-18 | BHATT ELIZABETH | President | Sale | 4,000 | $115,860 |
| 2026-02-18 | BHATT ELIZABETH | President | Option Exercise | 4,000 | $27,240 |
| 2025-11-10 | LONG DANIEL D | Officer | Sale | 3,501 | $63,223 |
SEC Filings
Recent regulatory filings from the SEC EDGAR database
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning SEPN from our newsroom.